Home News Page 3

News

General Views during at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesey 2019 © ASH/Danny Morton.

ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin Lymphoma

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers...
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

What to Expect at ASH 2019: Seattle Genetics

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S....

Enfortumab Vedotin + Pembrolizumab to be Evaluated in Phase III Registration Trial in...

Enfortumab vedotin (also known as AGS-22ME; Seattle Genetics/Astellas), an antibody-drug conjugate (ADC), will be evaluated in a phase III...

Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma

Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of...
Featured Image: London Tower Bridge. Photo Courtesy: 2018 Fotolia

Zymeworks, Regeneron, Boehringer Ingelheim Pharma and Many Others are Betting on Antibody-Drug-Conjugates

Antibody-Drug -Conjugates (ADCs) have the potential to reduce off-target toxicities in patients by limiting the exposure of normal tissues...

Health Canada Approves Brentuximab Vedotin + Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Health Canada has approved the supplemental New Drug Submission that expands the use of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda)...

ADC Express: Rapid ADC Production from a Single Source

Earlier this year, during the 10th annual World ADC meeting held in San Diego, CA, MilliporeSigma, launched a new...

What’s New in ADCs: 10th Annual World ADC Wrap-up

Hello ADC World:We have something a little different in store for today.  Today is a feature on the 10th...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and TROP2

With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other...